Evidence map›Paper›PMID 24291224›Full record

ArticleGrowth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society2014

Discordance of IGF-1 and GH stimulation testing for altered GH secretion in obesity.

Takara L Stanley, Meghan N Feldpausch, Caitlin A Murphy, Steven K Grinspoon, Hideo Makimura

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. The effect of growth hormone on bioactive IGF in overweight/obese women.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2018
    Trial
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Takara L StanleyProgram in Nutritional Metabolism and Neuroendocrine Unit, Massachusetts General Hospital, Boston, MA 02114, United States; Harvard Medical School, Boston, MA 02114, United States; Pediatric Endocrine Unit, Massachusetts General Hospital, Boston, MA 02114, United States.
Meghan N FeldpauschProgram in Nutritional Metabolism and Neuroendocrine Unit, Massachusetts General Hospital, Boston, MA 02114, United States; Harvard Medical School, Boston, MA 02114, United States.
Caitlin A MurphyProgram in Nutritional Metabolism and Neuroendocrine Unit, Massachusetts General Hospital, Boston, MA 02114, United States; Harvard Medical School, Boston, MA 02114, United States.
Steven K GrinspoonProgram in Nutritional Metabolism and Neuroendocrine Unit, Massachusetts General Hospital, Boston, MA 02114, United States; Harvard Medical School, Boston, MA 02114, United States.
Hideo MakimuraProgram in Nutritional Metabolism and Neuroendocrine Unit, Massachusetts General Hospital, Boston, MA 02114, United States; Harvard Medical School, Boston, MA 02114, United States. Electronic address: hmakimura@partners.org.
Harvard University · US

Funding

HARVARD CLINICAL AND TRANSLATIONAL SCIENCE CENTER (UL1)UL1RR025758 · NCRR · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2008 to 2011
$91.4M
ZD6416 Analgesic--Painful Distal Symmetrical PolyneuropaM01RR001066 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI BROWN, EMERY N · 1985 to 2008
$37.4M
ROLE OF DIETARY CONSTITUENTS ON GENE EXPRESSION IN INTESTINAL EPITHELIUMP30DK040561 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI CHRISTOPHER P DUGGAN · 1994 to 2026
$31.6M
Consequences and Treatment of Growth Hormone Deficiency in the Metabolic SyndromeR01HL085268 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI GRINSPOON, STEVEN K. · 2007 to 2010
$2.4M
Strategies to Improve CAD Risk In HIV DiseaseK24DK064545 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI GRINSPOON, STEVEN K. · 2003 to 2012
$1.6M
Growth Hormone, Mitochondria, and Cardio-metabolic Complications of ObesityK23DK087857 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI MAKIMURA, HIDEO · 2010 to 2014
$796k
Metabolic Effects of Augmenting Pulsatile Growth Hormone Secretion in HIV-InfectiK23DK089910 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI STANLEY, TAKARA LEAH · 2010 to 2014
$795k
NCRR NIH HHS M01 RR001066NCRR NIH HHS M01RR01066NCRR NIH HHS UL1 RR025758NCRR NIH HHS UL1RR025758NHLBI NIH HHS R01 HL085268NHLBI NIH HHS R01HL085268NIDDK NIH HHS K23 DK087857NIDDK NIH HHS K23DK087857NIDDK NIH HHS K23 DK089910NIDDK NIH HHS K23DK089910NIDDK NIH HHS K24 DK064545NIDDK NIH HHS K24DK064545NIDDK NIH HHS P30 DK040561NIDDK NIH HHS P30DK040561
6 · The paper itself

Abstract

objectiveTo investigate the concordance/discordance of IGF-1 and peak stimulated GH in identifying subjects with reduced GH secretion and to determine the physiological significance of any discordance in obese subjects. DESIGN, PATIENTS AND

methods95 obese and 43 normal weight men and women underwent measurement of IGF-1 and GH stimulation testing with GH releasing hormone (GHRH)-arginine. Reduced IGF-1 and GH secretion were defined using pre-determined cut-points. Cardiovascular disease risk was determined by measuring carotid intima-media thickness (cIMT). In a second study, IGF-1 was measured in 52 obese men and women who underwent GH stimulation testing and overnight frequent blood sampling. The association of IGF-1 and peak stimulated GH with parameters of endogenous GH secretion was assessed.

results60% of obese subjects had normal IGF-1 and peak stimulated GH while 8.4% of obese subjects had reduced IGF-1 and GH secretion. Discordance rate for IGF-1 and peak GH was 31.6%. Subjects with both low IGF-1 and low peak GH had the highest cIMT, while subjects with both normal IGF-1 and peak GH had the lowest cIMT. Subjects with reduction in either IGF-1 or peak GH, had intermediate cIMT (P=0.02). IGF-1 and peak stimulated GH were associated with maximum and mean overnight serum GH and GH AUC as well as maximum peak mass and median pulse mass. Peak stimulated GH, but not IGF-1, was also associated with nadir overnight serum GH concentration and basal GH secretion.

conclusionPeak stimulated GH and IGF-1 demonstrate significant discordance in identification of subjects with reduced GH secretion in obesity. Subjects with reduction of either IGF-1 or peak GH had higher cIMT compared to subjects with both normal IGF-1 and peak GH. Subjects with reductions in both IGF-1 and peak GH had the highest cIMT. Peak GH, compared to IGF-1, has broader associations with various parameters of endogenous GH secretion which support its utility in identifying those with reduced GH secretion.

Indexed as

AdolescentAdultBody Mass IndexCarotid ArteriesCase-Control StudiesFemaleHuman Growth HormoneHumansInsulin-Like Growth Factor IMaleMiddle AgedObesityTunica IntimaTunica MediaYoung AdultHuman Growth HormoneInsulin-Like Growth Factor IAutoDeconCarotid intima-media thicknessDeconvolution analysesFrequent samplingGHGHRH–arginineGH stimulation testIGF-1

Identifiers

PMID24291224
PMCPMC3946615
OpenAlexW1995437346

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.